Speakers: Katherine R Tuttle, Jay H Shubrook
Katherine Tuttle and Jay Shubrook reconvene to discuss what the landmark findings from recent renal outcomes trials mean for clinical practice (16:51).
Skip to sections on
- The impact of recent cardiovascular outcome trials and their relationship to renal outcome trials in SGLT2 inhibitors
- The CREDENCE trial: A new precedent for treating renal failure in patients with type 2 diabetes
- Why have clinical outcomes for kidney disease treatment lagged behind other microvascular diabetes complications?
- Which patients are likely to receive the most benefit from the agents that have demonstrated renal benefit?
More videos in the "diabetic kidney disease" series
- Diabetic kidney disease: A call to primary care
- Team-based care for patients with type 2 diabetes and kidney disease
About the experts |
|